SG11201903800XA - ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF - Google Patents

ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF

Info

Publication number
SG11201903800XA
SG11201903800XA SG11201903800XA SG11201903800XA SG11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA SG 11201903800X A SG11201903800X A SG 11201903800XA
Authority
SG
Singapore
Prior art keywords
cd66c
antibody
antibody binding
binding specifically
antigen
Prior art date
Application number
SG11201903800XA
Other languages
English (en)
Inventor
Sangsoon Yoon
Kwon Pyo Hong
Soseul Kim
Gil Yong Ji
Young Hoon Lim
Original Assignee
Dinona
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dinona filed Critical Dinona
Publication of SG11201903800XA publication Critical patent/SG11201903800XA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201903800XA 2016-11-14 2017-11-14 ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF SG11201903800XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160151359 2016-11-14
PCT/KR2017/012891 WO2018088877A2 (fr) 2016-11-14 2017-11-14 Anticorps se liant spécifiquement à cd66c et utilisation associée

Publications (1)

Publication Number Publication Date
SG11201903800XA true SG11201903800XA (en) 2019-05-30

Family

ID=62110206

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201903800XA SG11201903800XA (en) 2016-11-14 2017-11-14 ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF

Country Status (13)

Country Link
US (1) US11220543B2 (fr)
EP (1) EP3560957A4 (fr)
JP (2) JP2019535319A (fr)
KR (1) KR102019032B1 (fr)
CN (1) CN110382533B (fr)
AU (1) AU2017358359B2 (fr)
BR (1) BR112019009771A2 (fr)
CA (1) CA3043691C (fr)
IL (1) IL266516B (fr)
MX (1) MX2019005491A (fr)
PH (1) PH12019501050A1 (fr)
SG (1) SG11201903800XA (fr)
WO (1) WO2018088877A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017012278A (es) 2015-03-23 2018-05-23 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos.
WO2019221574A1 (fr) * 2018-05-14 2019-11-21 다이노나(주) Utilisation pour la prévention et le traitement de maladies associées à des cellules myéloïdes suppressives
KR102373502B1 (ko) * 2018-05-14 2022-03-11 주식회사 금호에이치티 골수유래억제세포 관련 질환의 예방 및 치료 용도
KR20210091152A (ko) * 2018-11-14 2021-07-21 바이엘 악티엔게젤샤프트 암의 치료를 위한 항-ceacam6 및 항-pd-1 또는 항-pd-l1 항체의 제약 조합물
KR102027248B1 (ko) * 2018-12-14 2019-10-01 건양대학교 산학협력단 유방암 줄기세포 검출용 바이오마커 및 이의 용도
CN112521509B (zh) * 2020-12-23 2022-07-08 姚雪英 一种抗ceacam5人源化抗体、其缀合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038996B2 (en) 2004-03-27 2011-10-18 University Of Arizona Composition and method for cancer treatment
US8883162B2 (en) * 2005-10-19 2014-11-11 Ibc Pharmaceuticals, Inc. Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
US8748356B2 (en) * 2007-10-19 2014-06-10 Janssen Biotech, Inc. Methods for use in human-adapting monoclonal antibodies
US8404812B2 (en) 2010-02-26 2013-03-26 Dinona Inc. Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same
KR101214177B1 (ko) 2010-02-26 2012-12-21 다이노나(주) ＣＤ66ｃ의 폐선암 특이적 에피토프 및 이를 인식하는 항체
EP2640744A4 (fr) * 2010-11-19 2014-05-28 Eisai R&D Man Co Ltd Neutralisation d'anticorps anti-ccl20
CN104470949A (zh) * 2012-05-15 2015-03-25 百时美施贵宝公司 通过破坏pd-1/pd-l1信号传输的免疫治疗
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
JP6879739B2 (ja) 2013-11-25 2021-06-02 フェイムウェイヴ リミテッド 癌治療のための抗ｃｅａｃａｍ１および抗ｐｄ抗体を含む組成物
KR101710936B1 (ko) 2014-09-12 2017-02-28 전영권 태양전지 및 그 제조방법
MX2017012278A (es) * 2015-03-23 2018-05-23 Bayer Pharma AG Anticuerpos anti-ceacam6 y sus usos.
KR101783907B1 (ko) * 2016-03-15 2017-10-10 다이노나(주) ＣＤ66ｃ에 대한 항체와 화학치료제를 포함하는 폐암 예방 또는 치료용 약학조성물
WO2017209318A1 (fr) 2016-05-30 2017-12-07 다이노나(주) Anticorps se liant à des anhydrases carboniques, et son utilisation

Also Published As

Publication number Publication date
WO2018088877A3 (fr) 2018-10-04
CA3043691A1 (fr) 2018-05-17
IL266516A (en) 2019-08-29
JP2019535319A (ja) 2019-12-12
CN110382533A (zh) 2019-10-25
MX2019005491A (es) 2019-08-12
WO2018088877A2 (fr) 2018-05-17
CA3043691C (fr) 2022-11-29
JP2021177770A (ja) 2021-11-18
JP7450585B2 (ja) 2024-03-15
EP3560957A4 (fr) 2020-10-21
AU2017358359A1 (en) 2019-05-30
US11220543B2 (en) 2022-01-11
EP3560957A2 (fr) 2019-10-30
WO2018088877A9 (fr) 2018-11-08
AU2017358359B2 (en) 2021-04-01
PH12019501050A1 (en) 2019-12-11
BR112019009771A2 (pt) 2019-09-17
KR102019032B1 (ko) 2019-09-06
KR20180054492A (ko) 2018-05-24
CN110382533B (zh) 2023-09-22
IL266516B (en) 2021-12-01
US20190263905A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
SG11201903800XA (en) ANTIBODY BINDING SPECIFICALLY TO CD66c AND USE THEREOF
MX2019010972A (es) Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos.
MX2018003470A (es) Nuevo anticuerpo anti-mesotelina y composicion que comprende el mismo.
ZA202005259B (en) Anti-ctla4 antibodies and methods of making and using the same
PH12018500664A1 (en) Anti-lag3 antibodies and uses thereof
EA201790799A1 (ru) Композиции и способы для применения для усиления иммунного ответа и терапии злокачественных опухолей
MX2022004072A (es) Anticuerpos de factor xi y metodos de uso.
MX2019001769A (es) Nuevos receptores de linfocitos t e inmunoterapia basada en el uso de los mismos.
MX2017016502A (es) Anticuerpos contra cd40 con actividad agonista mejorada.
PH12017500890A1 (en) Antibody drug conjugates
MX2017016253A (es) Anticuerpos para cd40.
MD4733B1 (ro) Anticorpi anti-TIGIT
RU2757308C2 (ru) Введение сконструированных т-клеток для лечения рака центральной нервной системы
PH12019500571A1 (en) Anti-pd-1 antibodies
PH12019500312A1 (en) T cell receptors and immune therapy using the same
EA201291195A1 (ru) Усовершенствованная терапия рака на основе опухолеассоциированных антигенов, полученных из циклина d1
MX2023001540A (es) Vacunas contra el cancer y metodos de tratamiento que las utilizan.
WO2018027124A8 (fr) Anticorps anti-o2 et utilisations associées
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
MX2020001287A (es) Receptor de linfocitos t (tcrs) especificos de braf y usos de los mismos.
PH12019502274A1 (en) Antibodies binding to steap-1
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
MX2022004086A (es) Anticuerpos anti inmunorreceptor de celulas t con dominios de inmunoglobulina y motivo inhibidor basado en tirosina de inmunorreceptor (tigit) y sus usos.
NZ730247A (en) Antibodies to ticagrelor and methods of use
MX2021003281A (es) Anticuerpos anti-cd45rc humanos y usos de los mismos.